Process for generating therapeutic compositions of engineered cells

Patent metadata

Field	Value
Publication number	US-12258580-B2
Application number	US-201816760240-A
Country	US
Kind code	B2
Filing date	Oct 31, 2018
Priority date	Nov 1, 2017
Publication date	Mar 25, 2025
Grant date	Mar 25, 2025

Abstract

The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the incubation and/or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

First claim

What is claimed:

1. A method for producing a composition of engineered cells, the method comprising:
(a) incubating an input composition comprising T cells enriched for one or both of CD4+ and CD8+ primary human T cells, thereby generating a stimulated composition, wherein:
the primary human T cells are from a human subject having a disease or condition; and
the incubating is carried out under one or more stimulating conditions, the stimulating conditions comprising the presence of (i) an anti-CD3 antibody or antibody fragment thereof and an anti-CD28 antibody or antibody fragment thereof, and (ii) recombinant IL-2 and recombinant IL-15, wherein the concentration of recombinant IL-2 is from about 10 IU/mL to about 200 IU/mL and the concentration of recombinant IL-15 is from about 1 IU/mL to about 25 IU/mL;
(b) introducing a recombinant receptor into cells of the stimulated composition, thereby generating an engineered composition comprising engineered T cells, wherein the recombinant receptor is capable of binding to a target antigen that is expressed on a cell of the disease or condition; and
(c) cultivating the engineered composition under conditions to promote expansion of the engineered T cells, thereby producing an output composition comprising the engineered T cells that is suitable for an autologous cell therapy to treat the disease or condition of the subject, wherein:
(i) the cultivating is carried out in the presence of:
(1) recombinant IL-2 and recombinant IL-15, wherein the concentration of recombinant IL-2 is from about 50 IU/mL to about 500 IU/mL and the concentration of recombinant IL-15 is from about 5 IU/mL to about 50 IU/mL; and
(2) a surfactant, wherein the surfactant is a poloxamer added during the cultivating step;

(ii) at least a portion of the cultivating is performed with perfusion; and
(iii) the cultivating is performed for 2 days to 8 days, inclusive, wherein the cultivating is performed at least until the output composition comprises 4-fold or greater viable T cells compared to the composition prior to the cultivating; and
(d) collecting cells of the output composition after at most 8 days of the cultivating.

2. The method of claim 1 , wherein the incubating is further carried out in the presence of recombinant IL-7.

3. The method of claim 2 , wherein:
the concentration of recombinant IL-7 is from about 100 IU/mL to about 1000 IU/mL.

4. The method of claim 1 , wherein the input composition comprises about 200×10 6 cells to about 300×10 6 cells.

5. The method of claim 1 , wherein the input composition comprises greater than about 70% primary human T cells.

6. The method of claim 1 , wherein the input composition comprises greater than about 90% primary human T cells.

7. The method of claim 1 , wherein the incubating is carried out in the presence of one or more antioxidants.

8. The method of claim 7 , wherein the one or more antioxidants comprise a glutathione precursor.

9. The method of claim 7 , wherein the one or more antioxidants comprise N-acetylcysteine (NAC), 2,3-dimercaptopropanol (DMP), L-2-oxo-4-thiazolidinecarboxylate (OTC), lipoic acid, S-allyl cysteine, or methylmethionine sulfonium chloride.

10. The method of claim 7 , wherein the one or more antioxidants comprise N-acetyl cysteine (NAC).

11. The method of claim 10 , wherein the concentration of NAC is from 0.2 mg/mL to 2.0 mg/mL.

12. The method of claim 1 , wherein the anti-CD3 antibody or antibody fragment thereof and the anti-CD28 antibody or antibody fragment thereof are present on the surface of a bead.

13. The method of claim 12 , wherein the ratio of beads to cells is from 2:1 to 0.5:1 or from about 2:1 to about 0.5:1.

14. The method of claim 1 , wherein the introducing comprises transducing cells of the stimulated composition with a viral vector comprising a polynucleotide encoding the recombinant receptor.

15. The method of claim 14 , wherein the viral vector is a retroviral vector.

16. The method of claim 1 , wherein the recombinant receptor is a T-cell receptor (TCR) or antigen-binding fragment thereof.

17. The method of claim 1 , wherein the recombinant receptor is a chimeric antigen receptor (CAR).

18. The method of claim 1 , wherein the recombinant receptor is an anti-CD19 CAR.

19. The method of claim 1 , wherein the introducing is carried out in the presence of a transduction adjuvant.

20. The method of claim 19 , wherein the transduction adjuvant is protamine sulfate.

21. The method of claim 20 , wherein the concentration of protamine sulfate is from 1 μg/mL to 50 μg/mL.

22. The method of claim 1 , wherein the cultivating is further carried out in the presence of recombinant IL-7.

23. The method of claim 22 , wherein:
the concentration of recombinant IL-7 during the cultivating is from about 500 IU/mL to about 2000 IU/mL.

24. The method of claim 1 , wherein the concentration of the poloxamer is from 0.5 μL/mL to 5 μL/mL.

25. The method of claim 1 , wherein the anti-CD3 antibody or antibody fragment thereof and the anti-CD28 antibody or antibody fragment thereof are removed from the engineered composition prior to the cultivating.

26. The method of claim 25 , wherein the anti-CD3 antibody or antibody fragment thereof and the anti-CD28 antibody or antibody fragment thereof are removed from 3 days to 6 days after the initiation of the incubating.

27. The method of claim 1 , wherein the output composition comprises at least 1200×10 6 viable T cells.

28. The method of claim 1 , wherein the amount of time between the initiation of the incubating and the collecting is from 9 days to 13 days or from about 9 days to about 13 days.

29. The method of claim 1 , wherein the method is performed in less than 21 days, inclusive.

30. The method of claim 1 , further comprising formulating cells of the output composition for cryopreservation or administration to the human subject.

31. The method of claim 1 , wherein for a plurality of input compositions from different biological samples from a plurality of different human subjects having the disease or condition, output compositions are each produced in less than 21 days after the incubating of the plurality of input compositions for greater than 85% of the plurality of input compositions.

32. The method of claim 1 , wherein the disease or condition is a cancer.

33. The method of claim 1 , wherein during at least a portion of the cultivating, the cells are monitored for cell viability, concentration, density, number, or a combination of any of the foregoing.

34. The method of claim 33 , wherein the monitoring is carried out by differential digital holography microscopy (DDHM).

35. The method of claim 1 , wherein the input composition is a first input composition enriched in CD8+ primary human T cells, and the method further comprises:
(a) separately incubating, under stimulating conditions, a second input composition comprising T cells enriched for CD4+ primary human T cells, wherein:
the T cells enriched for CD4+ primary human T cells are isolated from the same biological sample from the human subject as the T cells enriched for CD8+ primary human T cells; and
the stimulating conditions comprise the presence of (i) a stimulatory reagent capable of activating on

Assignees

• Juno Therapeutics Inc

Inventors

• Lee Sarah Y
• Beauchesne Pascal
• Bonyhadi Mark L
• Crisman Ryan L
• Larson Ryan P
• Mallaney Mary
• Ramsborg Christopher Glen
• Weber Clinton
• Wesner John Matthew
• Yee Nathan

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N2501/2307

  Interleukin-7 (IL-7) · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• C12N2501/515

  CD3, T-cell receptor complex · CPC title